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Simvastatin: A Risk Factor for Angioedema? 
SARAH A NISLY, AREEBA KARA, TAMARA B KNIGHT 
Objective: To report a case of simvastatin-induced angioedema in a patient with near nightly episodes of 
orofacial angioedema. 
Case Summary: A 75-year-old African American female presented to the emergency department with 
recurrent face, lip, and tongue swelling. The patient described frequent episodes of orofacial edema, with 4 
emergency department visits over the previous 6 months. Her home medications were reviewed and 
simvastatin was identified as a possible contributing medication. Simvastatin was discontinued with 
resolution of the symptoms during hospitalization and a significant reduction in episodes. 
Discussion: Drug-induced angioedema has been documented with several agents, most commonly 
angiotensin-converting enzyme inhibitors. The association with different drug classes has led to several 
postulated pathways for the development of angioedema. Notable mechanisms include mediation by 
bradykinin, inhibition of arachidonic acid metabolism, and complement activation. Each pathway 
culminates in increasing vascular permeability causing fluid accumulation in subcutaneous tissues. While 
statin use has been associated with drug-induced angioedema in postmarketing reports, there are no 
published cases involving simvastatin. Use of the Naranjo probability scale demonstrated a probable 
relationship between simvastatin use and the patient’s recurrent angioedema. 
Conclusions: While statin use is not commonly associated with angioedema, clinicians must be aware of this 
possible adverse reaction. Consideration must also be given to potential drug interactions, increasing the risk 
of this adverse event. 
Angioedema is the abrupt onset of swelling involving the mucosa and submucosa of the skin. It can affect 
the face, lips, tongue, pharynx, and larynx, causing life threatening airflow obstruction.1,2 Angioedema is 
mediated by inflammatory cytokines, such as prostaglandin D2, leukotrienes, cytokines, bradykinin, and 
complement components, which cause vasodilation and increase the permeability of capillaries. This 
allows plasma to leave the intravascular space and cause submucosal swelling.2 It may be accompanied 
by urticaria, identifying it as an acute allergic response mediated by histamine. Urticaria differs from 
angioedema in that it only affects the skin and not the subcutaneous or submucosal tissue and is almost 
always pruritic.2 Angioedema without urticaria can be a result of an adverse drug reaction as is the case 
with angioedema due to angiotensin-converting enzyme (ACE) inhibitors.1 
 
Approximately 17.5% of patients with cutaneous drug eruptions have angioedema.3 In addition, it is 
estimated that angioedema is caused by a drug in 32% of cases.4 Lastly, ACE-inhibitor use is associated 
with 25-38% of all angioedema-related emergency department (ED) visits.5 Simvastatin, as well as 
atorvastatin, fluvastatin, lovastatin, rosuvastatin, and pravastatin have been associated with 
postmarketing reports of hypersensitivity reactions, including angioedema.6-11 A review of the literature 
reveals 4 case reports of statin-induced angioedema. These reports described a case of atorvastatin 
induced angioedema with dermographism and urticaria, atorvastatin-induced angioedema with rash and 
eosinophilia, pravastatin-induced angioedema, and lovastatin-induced angioedema with urticaria. Time to 
onset of these reactions varied from 2 days to 9 months.12-14  
 
Despite postmarketing reports, there have been no published case reports of simvastatin-induced 
angioedema. We present a case of angioedema without urticarial associated with simvastatin use. 
Case Report  
A 75-year-old African American female with a medical history of diabetes mellitus type 2, diabetic 
retinopathy,obstructive lung disease, hypertension, obstructive sleep apnea, dyslipidemia, diastolic heart 
failure, pulmonary hypertension, and a single transient ischemic attack was admitted to the hospital with 
recurrent face, lip, and tongue swelling. 
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Her known allergies to medications included penicillin, which caused rash and itching. ACE inhibitors and 
angiotensin receptor blockers (ARBs) were listed as drug intolerances secondary to the development of 
angioedema. Her routine home medications included insulin NPH, simvastatin, clopidogrel, isosorbide 
dinitrate-hydrala zine,furosemide, potassium chloride, hydrochlorothiazide, amlodipine, and carvedilol. 
Diphenhydramine and famotidine were used as needed. With the exception of diphenhydramine, she 
denied use of any other over-the-counter agents. Of note, her simvastatin dose had been increased from 
10 mg to 20 mg each night 9 months prior to presentation. 
 
At presentation, the patient described waking up in the middle of almost each night, with facial, tongue, 
and lip swelling. She denied associated shortness of breath, rash, difficulty swallowing, abdominal pain, 
wheezing, or pruritus. She reported frequent self-medication with oral diphenhydramine in an attempt to 
abort the episodes. If her symptoms did not resolve with diphenhydramine, she would present to the ED. 
In the 6 months prior to admission, she had presented to the ED 4 times, each time reporting that self-
medication did not resolve her symptoms. During each visit to the ED, she received corticosteroids, 
diphenhydramine, and famotidine prior to being released home after a period of observation. On the day 
of presentation, she was referred for inpatient admission after intravenous administration of 
diphenhydramine 50 mg, famotidine 20 mg, and dexamethasone 10 mg. In reviewing her previous 
history, clinicians determined that the first episode occurred 19 months prior to admission, which 
prompted the discontinuation of trandolapril. Despite this, the episodes continued and increased in 
frequency in the 9 months prior to hospitalization, correlating with the increase in simvastatin dose. 
 
Her review of systems was negative except for occasional lower-extremity edema. On physical 
examination, the patient was found to be hemodynamically stable, with a blood pressure of 140/73 
mmHg, heart rate 75 beats/min, respiratory rate 16 breaths/min, and oxygen saturation 100% on room 
air. Her weight was recorded at 120.7 kg. She had significant facial, tongue, and lip edema. There was no 
wheezing appreciated or rash noted on exam. Her abdominal and cardiovascular examinations were also 
benign.  
 
Basic chemistry screen and blood counts were within normal limits, with a creatinine level of 0.9 mg/dL, 
serum calcium of 9.6 mg/dL, serum glucose of 275 mg/dL, hemoglobin of 13.5 g/dL, and white blood cell 
count of 8.8 109/L. A diagnosis of hereditary angioedema was excluded by normal measurements of the 
C1q binding assay, complement C4 levels, and C1 esterase inhibitor levels. 
▲ 
ACE inhibitors are traditionally 
associated with drug-induced 
angioedema. 
▼ 
The patient was observed in the hospital for 48 hours, with continuous monitoring of her oxygen 
saturations. No further corticosteroids were administered and simvastatin was discontinued. Cetirizine 
was initiated and famotidine was continued orally. Over the next 36 hours her facial, tongue, and lip 
swelling resolved. Given the fact that her symptoms occurred reliably in the middle of the night and 
worsened after a dosage increase, simvastatin was considered as a possible inciting agent. She was 
instructed to discontinue simvastatin and her primary care physician was notified. She was discharged 
home on her admission medication list, with the exception of simvastatin. Additionally, she was instructed 
to use cetirizine as needed for facial swelling. Six months after discontinuation of simvastatin, the patient 
reported continued resolution of her nightly episodes. She did have 1 presentation to the ED for 
nonnocturnal angioedema, a drastic improvement in frequency. 
 
Discussion  
There are several potential mechanisms for drug-induced angioedema. Our patient had experienced 
recurrent angioedema that persisted after the cessation of trandolapril. ACE inhibitors are traditionally 
associated with drug-induced angioedema. Theoretically, the effect is mediated by bradykinin. ACE 
inhibitors inhibit the degradation of bradykinin, leading to an increase in vasodilation, histamine release, 
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and vascular permeability. Although the ARB drug class does not inhibit the degradation of bradykinin, it 
has been associated with angioedema. This raises the question of alternate pathways. 
 
Several other medications have been associated with drug-induced angioedema, including calcium 
channel antagonists, thienopyridines, and hydrochlorothiazide.15-19 Identification of additional medications 
associated with angioedema has led to other proposed mechanisms for drug-induced angioedema. Many 
mechanisms lead to increased vascular permeability, causing fluid accumulation in the subcutaneous 
tissues. 
 
At the time of symptom onset, our patient was receiving 4 medications that have been linked to 
angioedema. Amlodipine, clopidogrel, hydrochlorothiazide, and simvastatin each have postmarketing 
reports of angioedema. Amlodipine has been linked to angioedema development in adults and children 
receiving therapy for days to months before symptom onset.15-17 In all 3 cases, cessation of amlodipine led 
to complete resolution of angioedema. Due to the long half-life of amlodipine, symptoms persisted for 2-7 
days after stopping therapy. While the mechanism remains unknown, it is postulated that amlodipine 
stimulates the kinin system via activation of kallikrein. Additional consideration of the simvastatin and 
amlodipine drug interaction is necessary. Currently, the simvastatin manufacturer recommends limiting 
the dose of simvastatin to 20 mg in patients receiving amlodipine.6 While our patient did not exceed the 
maximum daily dose, amlodipine leads to decreased metabolism of simvastatin. This drug interaction may 
result in higher serum drug concentrations of simvastatin and potentially more adverse effects, including 
angioedema. Currently, there is not enough information to know whether statin-induced angioedema 
is dose dependent or related to serum drug concentrations. However, it seems plausible, based on case 
reports of drug induced angioedema that resolved with dose reduction or medication rechallenge at lower 
doses.18,19 Our patient received amlodipine throughout her hospitalization and was discharged on her 
home regimen. 
 
Less evidence exists for clopidogrel-induced angioedema; however, it has been reported in a 71-year-old 
male receiving clopidogrel for coronary artery disease.20 At the time of symptom onset, he was receiving 
clopidogrel, verapamil, aspirin, and an unknown statin. After developing angioedema, all therapy was 
stopped and he was admitted to the hospital for a placebo-controlled testing of his therapy 
to identify the culprit. Three hours after receiving clopidogrel, he developed angioedema, solidifying the 
diagnosis. Again, our patient received clopidogrel throughout her hospitalization and was discharged on 
her home regimen. 
 
Lastly, hydrochlorothiazide-induced angioedema has been reported in a patient with a known 
angioedema reaction to sulfonamides.21 Hydrochlorothiazide was suspected after continuation of 
symptoms despite cessation of valsartan in an 82-year-old female. The authors speculated that the sulfur 
dioxide moiety in hydrochlorothiazide was responsible for the subsequent angioedema reaction in this 
patient. Our patient had no known previous reactions to sulfonamides, continued on her home 
hydrochlorothiazide regimen throughout hospitalization, and was discharged on her home regimen. 
▲ 
While the mechanism of statin induced 
angioedema is 
unknown, the effect may be 
mediated by bradykinin via the 
upregulation of bradykinin type 2 
receptors. 
▼ 
To date, few case reports of statin-induced angioedema have been published. Detailed review of this 
patient case, using the Naranjo probability scale, shows a probable association between simvastatin and 
angioedema. Positive associated factors included previous postmarketing reports, occurrence after 
simvastatin administration, improvement after stopping therapy, and symptom increase with dose 
escalation.22 
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While the mechanism of statin-induced angioedema is unknown, the effect may also be mediated by 
bradykinin via the upregulation of bradykinin type 2 receptors. Lovastatin has been shown to upregulate 
the expression of bradykinin type 2 receptors in human coronary arteries. Upregulation of these receptors 
could potentiate the actions of circulating bradykinin, resulting in release of nitric oxide, prostacyclin, and 
endothelium-derived hyperpolarizing factor, which then cause vasodilation and, potentially, angioedema.23 
 
Our patient did not present with urticaria or rash, indicating a non–histamine-mediated mechanism of 
angioedema. While the patient did report self-medicating with antihistamines when she developed 
angioedema, this was frequently unsuccessful. A bradykinin-mediated mechanism is plausible, based on 
the patient’s history of angioedema with ACE inhibitors. Concomitant use of statin medications has been 
a proposed predisposing risk factor for ACE–inhibitor-induced angioedema, lending consideration to other 
drug interactions.24  An increase in bradykinin type 2 receptors from statin use, coupled with an activation 
of the kinin system from amlodipine may precipitate the development of angioedema. Based on this 
proposed mechanism, it is plausible that statin use may predispose patients to experiencing angioedema 
when another inciting factor that increases circulating bradykinin is present. Of the 4 case reports of 
statin-induced angioedema described previously, 1 did not state the patient’s concomitant medications. 
Of the remaining 3 cases, 2 of the patients were on another medication associated with the development 
of angioedema, including estrogen in 1 case and diltiazem in the other. These were not the suspected 
causative agents in these cases because the angioedema did not occur until after the addition of the 
statin medication and resolved after statin discontinuation.12-15  
 
Our patient reported near nightly symptoms and frequent ED visits prior to stopping simvastatin. The long 
duration between simvastatin discontinuation and her next ED visit demonstrates significant improvement 
in her frequent symptoms. 
 
Case reports of drug-induced angioedema are scattered throughout the literature. Most statin 
manufacturers note postmarketing reports of angioedema; however, specific case reports in the literature 
are lacking. We report a probable association between simvastatin and angioedema that improved 
significantly after cessation of simvastatin. While simvastatin may not have been the sole cause of 
angioedema in our patient, this adverse effect should be considered in patients with persistent 
angioedema who are receiving a statin medication, especially in combination with other medications 
associated with the development of angioedema. 
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